Boron Containing Doai Patents (Class 514/64)
  • Patent number: 12065500
    Abstract: Disclosed are methods of treating cancers and enhancing efficacy of T cell redirecting therapeutics.
    Type: Grant
    Filed: May 15, 2019
    Date of Patent: August 20, 2024
    Assignees: Janssen Biotech, Inc., Stichting VUmc
    Inventors: Homer Adams, Francois Gaudet, Niels Van de Donk, Kris Frerichs, Christie Verkleij
  • Patent number: 12054502
    Abstract: A multifunctional immunity-targeted micromolecule anti-cancer medicine Citrate Bestazomib and preparation method and application thereof. The structure of the multifunctional immunity-targeted micromolecule anti-cancer medicine Bestazomib Citrate is shown as follows: The multifunctional immunity-targeted micromolecule anti-cancer medicine Citrate Bestazomib has an activity-inhibiting effect on APN/CD13, also has an activity-inhibiting effect on tumor proteasome, and can be applied to the development of medicines for treating malignant tumors.
    Type: Grant
    Filed: August 5, 2019
    Date of Patent: August 6, 2024
    Assignee: SHANDONG HUBBLE KISEN BIOLOGICAL TECHNONLOGY CO., LTD.
    Inventors: Wenfang Xu, Jian Zhang, Yuqi Jiang, Xiaobo Xu, Xiaoyang Li, Leqiao Tan, Yongxue Huang, Xuejian Wang, Zhen Zhang
  • Patent number: 12023408
    Abstract: A solid dispersion of amorphous efinaconazole and a method for preparing the same are proposed. The solid dispersion includes an amorphous form of efinaconazole and at least one stabilization carrier selected from hydroxypropyl methylcellulose (HPMC), hydroxypropyl cellulose (HPC), ethyl cellulose (EC), hydroxypropyl methylcellulose acetate succinate (HPMC-AS), polyvinylpyrrolidone (PVP), polyacrylic acid (PAA), saccharin, and malonic acid. The solid dispersion undergoes minimal thermodynamic deformation when exposed to ambient temperature and humidity, achieving improved stability, while maintaining the inherent improved stability and bioavailability of amorphous efinaconazole.
    Type: Grant
    Filed: September 25, 2020
    Date of Patent: July 2, 2024
    Assignee: DAEBONG LS CO., LTD.
    Inventors: Eun Ju Park, Hyun Ji, Ji Eun Lee, Jin Oh Park
  • Patent number: 12005069
    Abstract: The present disclosure relates to ready-to-use liquid aqueous bortezomib compositions bortezomib and pharmaceutical excipients. Other aspects include methods of preparing such ready-to-use liquid aqueous bortezomib compositions, and methods of using such ready-to-use liquid bortezomib compositions in therapeutic applications.
    Type: Grant
    Filed: August 28, 2023
    Date of Patent: June 11, 2024
    Assignee: MAIA PHARMACEUTICALS, INC.
    Inventors: Srikanth Sundaram, Daniel Charles Stewart
  • Patent number: 11952392
    Abstract: Disclosed include crystalline (S)-2-amino-N-((3R,5R)-8-hydroxy-6-oxo-7-oxa-1-aza-8-boraspiro[4.7]dodecan-3-yl)-3-methylbutanamide in Form D and in Form E: (3R,5R)-8-hydroxy-3-((S)-4-isopropyl-2,2-dimethyl-5-oxoimidazolidin-1-yl)-7-oxa-1-aza-8-boraspiro[4.7]dodecan-6-one or a pharmaceutically acceptable salt thereof or the crystalline Form 1 thereof: and pharmaceutical compositions and methods of using the same.
    Type: Grant
    Filed: August 21, 2019
    Date of Patent: April 9, 2024
    Assignee: AstraZeneca AB
    Inventor: Dedong Wu
  • Patent number: 11858951
    Abstract: ?-Amino boronic acid derivatives are useful for inhibiting the activity of immunoproteasome (LMP7) and for the treatment and/or prevention of medical conditions affected by immunoproteasome activity such as inflammatory and autoimmune diseases, neurodegenerative diseases, proliferative diseases, and cancer.
    Type: Grant
    Filed: January 31, 2022
    Date of Patent: January 2, 2024
    Assignee: Merck Patent GmbH
    Inventors: Markus Klein, Oliver Schadt, Christina Esdar
  • Patent number: 11834466
    Abstract: A benzoxaborole formulation composition including a benzoxaborole, a non-ionic surfactant, or a non-ionic and ionic surfactant mixture, and a carrier is described herein. At least one of the non-ionic surfactant, the non-ionic and ionic surfactant mixture, and the carrier comprise a Lewis base or a N—H or O—H bond. The carrier is a solid or a liquid. Benzoxaborole compounds and methods of using the compounds and formulations of the compounds are described. For example, a method for reducing, preventing, ameliorating, or inhibiting an infestation by a pathogen by applying a compound or a formulation of a compound, wherein the pathogen is selected from insects, nematodes, bacteria, microbes, fungi, protozoa, viruses, and parasites, or any combinations thereof is described.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: December 5, 2023
    Assignee: 5Metis, Inc.
    Inventors: Marissa Aubrey, Chun Yu Liu, Chunliang Liu, Michael Samuels, Yong-Kang Zhang, Yasheen Zhou
  • Patent number: 11806342
    Abstract: A method to treat a patient with a Clostridium difficile infection comprising administering a therapeutically effective amount of diiodohydroxyquinoline, with or without one or more anti-infective agents.
    Type: Grant
    Filed: October 6, 2020
    Date of Patent: November 7, 2023
    Assignee: Purdue Research Foundation
    Inventors: Mohamed Seleem, Nader Abutaleb
  • Patent number: 11780858
    Abstract: The invention provides novel pyridinamine-pyridone and pyrimidinamine-pyridone compounds of formula (I), pharmaceutical compositions containing such compounds, and methods for using such compounds in treatment of diseases including cancer, type II diabetes, inflammatory disease, neurodegenerative disorders, cardiovascular disorders, autoimmune diseases and viral infections; wherein R1, R2, R3 and Z are as defined in the specification.
    Type: Grant
    Filed: November 18, 2021
    Date of Patent: October 10, 2023
    Assignee: Sprint Bioscience AB
    Inventors: Johan Lindström, Rickard Forsblom, Tobias Ginman, Fredrik Rahm, Jenny Viklund
  • Patent number: 11771089
    Abstract: The present application relates to large-scale methods of uniformly coating packaging surfaces with a benzoxaborole compound.
    Type: Grant
    Filed: June 14, 2021
    Date of Patent: October 3, 2023
    Assignee: AGROFRESH INC.
    Inventors: Daniel MacLean, Richard M. Jacobson, Timothy Malefyt
  • Patent number: 11773113
    Abstract: The present invention relates to four crystal forms of crisaborole in free form and the preparation method thereof. The present invention also relates to the pharmaceutical composition containing the crystal forms and the use thereof.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: October 3, 2023
    Assignee: Anacor Pharmaceuticals, Inc.
    Inventors: Minhua Chen, Yanfeng Zhang, Fei Lu, Nan Xia, Xiaoyu Zhang
  • Patent number: 11752164
    Abstract: The present disclosure relates to ready-to-use liquid aqueous bortezomib compositions bortezomib and pharmaceutical excipients. Other aspects include methods of preparing such ready-to-use liquid aqueous bortezomib compositions, and methods of using such ready-to-use liquid bortezomib compositions in therapeutic applications.
    Type: Grant
    Filed: March 22, 2023
    Date of Patent: September 12, 2023
    Assignee: MAIA PHARMACEUTICALS, INC.
    Inventors: Srikanth Sundaram, Daniel Charles Stewart
  • Patent number: 11680073
    Abstract: Disclosed are compounds for medical uses, for example, compounds of formula Ia, wherein A1, A2, A3, A4, A5, A6, A7, R6, R7 and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition, for example, cancer.
    Type: Grant
    Filed: October 26, 2021
    Date of Patent: June 20, 2023
    Assignee: ADT PHARMACEUTICALS, LLC
    Inventors: Michael Boyd, Xi Chen
  • Patent number: 11655260
    Abstract: Heterocyclic compounds are provided as arginase inhibitors, in particular to a compound represented by Formula (I), or a pharmaceutically acceptable salt, stereoisomer or tautomer, or prodrug thereof and a pharmaceutical composition including the compound.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: May 23, 2023
    Assignee: GUANGDONG NEWOPP BIOPHARMACEUTICALS CO., LTD.
    Inventors: Zhaoyin Wang, Nanxin Li, Jianbin Ma, Yanqiang Shao
  • Patent number: 11649563
    Abstract: Compounds for use in the textile field, and more particularly the use of compounds of the 4-bora-3a,4a-diaza-s-indacene family for the manufacture of fluorescent fibers, the fluorescent compound being chosen from those of formula I: Also, processes for producing the fluorescent fibers and also to the uses thereof, notably for the provision of security to products.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: May 16, 2023
    Assignee: CRIME SCIENCE TECHNOLOGY
    Inventors: Cosimo Prete, Alexis Depauw, Jeremy Malinge
  • Patent number: 11499197
    Abstract: The invention relates to a method for in vitro predicting the outcome of an individual having a multiple myeloma, comprising the steps of: a. measuring the expression level of genes coding for kinases, b. calculating a score value for each genes; and c. classifying the individual as having a good or a bad outcome.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: November 15, 2022
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER, UNIVERSITÉ DE MONTPELLIER
    Inventors: Jerome Moreaux, Hugues De Boussac, Alboukadel Kassambara
  • Patent number: 11434301
    Abstract: Disclosed herein are methods of treating a subject having a cancer characterized by a modification at biomarker 1q21, which comprises administering to the subject a therapeutically effective amount of an anti-CD46 antibody.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: September 6, 2022
    Assignee: The Regents of the University of California
    Inventors: Bin Liu, Daniel W. Sherbenou, Blake T. Aftab, Yang Su, Christopher R. Behrens
  • Patent number: 11414435
    Abstract: Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: August 16, 2022
    Assignee: VENATORX PHARMACEUTICALS, INC.
    Inventors: Christopher J. Burns, Denis Daigle, Bin Liu, Daniel McGarry, Daniel C. Pevear, Robert E. Lee Trout, Randy W. Jackson
  • Patent number: 11325942
    Abstract: Useful chiral specific boron-containing compounds, such as boronate, boronate esters, boranamines, borane diamines, boranamine thioesters, and boronic mono/di-thioesters, have been prepared. These compounds and compositions containing them are useful as anti-cancer or anti-amyloidosis agents.
    Type: Grant
    Filed: December 30, 2020
    Date of Patent: May 10, 2022
    Assignee: BEIJING ARTIVILA BIOPHARMA CO. LTD.
    Inventor: Guoxia Han
  • Patent number: 11318151
    Abstract: The disclosure relates to the field of pharmaceutical technology, in particular, to a compound pharmaceutical composition for treating skin inflammatory diseases, which is characterized in that an active ingredient of the compound pharmaceutical of the disclosure is composed of tofacitinib and crisaborole, and the composition has a stronger therapeutic effect and a lower dosage with a significant synergistic therapeutic effect. The pharmaceutical composition of the disclosure can be used to treat skin inflammatory diseases.
    Type: Grant
    Filed: May 9, 2019
    Date of Patent: May 3, 2022
    Assignees: HEFEI INDUSTRIAL PHARMACEUTICAL INSTITUTE CO., LTD, HEFEI AMVITE PHARMACEUTICAL CO., LTD
    Inventors: Guangwei He, Zhaoxing Chu, Qinlong Xu, Jiajia Mo, Yan Zhao, Lincui Bian, Yuanfeng Gu, Li Shao
  • Patent number: 11274109
    Abstract: ?-amino boronic acid derivatives are useful for inhibiting the activity of immunoproteasome (LMP7) and for the treatment and/or prevention of medical conditions affected by immunoproteasome activity such as inflammatory and autoimmune diseases, neurodegenerative diseases, proliferative diseases and cancer.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: March 15, 2022
    Assignee: Merck Patent GmbH
    Inventors: Markus Klein, Oliver Schadt, Christina Esdar
  • Patent number: 11229614
    Abstract: The present invention provides compositions and methods for treating hypertension and obstructive sleep apnea utilizing hydrogel compositions comprising drug amphiphiles with TRPM 7 antagonists for use in a subject, including use on the carotid body of a subject.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: January 25, 2022
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Vsevolod Polotsky, Honggang Cui, Roxana Elena Mitrut, Mi-kyung Shin
  • Patent number: 11207312
    Abstract: The present invention relates to metallo-?-lactamase inhibitor compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein Z, RA, X1, X2 and R1 are as defined herein. The present invention also relates to compositions which comprise a metallo-?-lactamase inhibitor compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with a beta lactam antibiotic and/or a beta-lactamase inhibitor. The invention further relates to methods for treating a bacterial infection comprising administering to a patient a therapeutically effective amount of a compound of the invention, in combination with a therapeutically effective amount of one or more ?-lactam antibiotics and optionally in combination with one or more beta-lactamase inhibitor compounds. The compounds of the invention are useful in the methods described herein for overcoming antibiotic resistance.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: December 28, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Alexander Pasternak, Shuzhi Dong, Jack D. Scott, Haiqun Tang, Zhiqiang Zhao, Dexi Yang, Xin Gu, Jinlong Jiang, Li Xiao
  • Patent number: 11208423
    Abstract: The invention provides novel pyridinamine-pyridone and pyrimidinamine-pyridone compounds of formula (I), pharmaceutical compositions containing such compounds, and methods for using such compounds in treatment of diseases including cancer, type II diabetes, inflammatory disease, neurodegenerative disorders, cardiovascular disorders, autoimmune diseases and viral infections; (I) wherein R1, R2, R3 and Z are as defined in the specification.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: December 28, 2021
    Assignee: Sprint Bioscience AB
    Inventors: Johan Lindström, Rickard Forsblom, Tobias Ginman, Fredrik Rahm, Jenny Viklund
  • Patent number: 11197854
    Abstract: The present invention relates to methods for identifying candidate therapeutics for a disease caused by a viral envelope protein. In particular, the method can include contacting a test envelope protein with the candidate and determining its activity.
    Type: Grant
    Filed: November 14, 2019
    Date of Patent: December 14, 2021
    Assignee: National Technology & Engineering Solutions of Sandia, LLC
    Inventors: Michael S. Kent, Susan Rempe, Juan M. Vanegas
  • Patent number: 11186596
    Abstract: Disclosed are compounds for medical uses, for example, compounds of formula (Ia), wherein A1, A2, A3, A4, A5, A6, A7, R6, R7 and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition, for example, cancer.
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: November 30, 2021
    Assignee: ADT Pharmaceuticals, LLC
    Inventors: Michael Boyd, Xi Chen
  • Patent number: 11154563
    Abstract: Provided herein are compounds, such as a compound of Formula (I), as described herein, or a pharmaceutically acceptable salt thereof, that are immunoproteasome (such as LMP2 and LMP7) inhibitors. The compounds described herein can be useful for the treatment of diseases treatable by inhibition of immunoproteasomes. Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: January 16, 2018
    Date of Patent: October 26, 2021
    Assignee: Principia Biopharma Inc.
    Inventors: Yan Lou, Timothy Duncan Owens, Kenneth Albert Brameld, David Michael Goldstein
  • Patent number: 11147802
    Abstract: Provided are a substituted oxadiazole chemical compound and composition containing said chemical compound and use thereof; said substituted oxadiazole chemical compound is the oxadiazole chemical compound as represented by formula (I), or its crystalline form, pharmaceutically acceptable salt, prodrug, stereoisomer, hydrate, or solvent compound. The disclosed substituted oxadiazole chemical compound and composition containing said chemical compound are capable of inhibiting indoleamine 2,3-dioxygenase; it also has better pharmacokinetic parameter attributes and is capable of improving the drug concentration of the chemical compound in an animal body, thus improving the therapeutic efficacy and safety of the drug.
    Type: Grant
    Filed: January 5, 2017
    Date of Patent: October 19, 2021
    Assignee: Shenzhen TargetRx, Inc.
    Inventors: Yihan Wang, Huanyin Li
  • Patent number: 11137400
    Abstract: The present disclosure relates to methods for predicting and/or determining responsiveness to an activator of JNK kinase activity. The present disclosure further relates to improved methods for treating a cancer patient with an activator of JNK kinase activity. The present disclosure also relates to methods for screening for a modulator of XBP1s protein phosphorylation.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: October 5, 2021
    Assignee: UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventor: Hongjiao Ouyang
  • Patent number: 11091505
    Abstract: Described herein are crystalline forms of (R)-3-(2-(trans-4-(2-aminoethylamino)cyclohexyl)acetamido)-2-hydroxy-3,4-dihydro-2H-benzo[e][1,2]oxaborinine-8-carboxylic acid. In some embodiments, the crystalline forms are formulated for treating a subject in need thereof with a bacterial infection.
    Type: Grant
    Filed: March 5, 2018
    Date of Patent: August 17, 2021
    Assignee: VenatoRx Pharmaceuticals, Inc.
    Inventors: Christopher J. Burns, Daniel C. Pevear, Luigi Xerri, Timothy Henkel, Daniel McGarry, Lawrence Rosen, Gerald Brenner, Jean-Baptiste Arlin, Ana Fernandez Casares
  • Patent number: 11066425
    Abstract: Provided is a novel compound that has an excellent ?-lactamase inhibitory effect. More specifically, provided is a compound represented by formula (1a), (1b) or (11) having an excellent ?-lactamase inhibitory effect or a pharmaceutically acceptable salt thereof. By using this compound either in combination with a ?-lactam drug or alone, a useful preventive or therapeutic agent for bacterial infections is provided. Also provided are useful preventive or therapeutic agents for treating various diseases with the combined use of the aforesaid compound and ?-lactam drugs.
    Type: Grant
    Filed: December 29, 2020
    Date of Patent: July 20, 2021
    Assignees: SUMITOMO DAINIPPON PHARMA CO., LTD., THE KITASATO INSTITUTE
    Inventors: Toshio Kanai, Sachiko Koike, Takayuki Fukaya, Shunichiro Uesugi, Shingo Mizushima, Hitoshi Suda, Yuki Mizukami, Yohei Ikuma, Toshiaki Sunazuka, Yoshihiko Noguchi
  • Patent number: 11046715
    Abstract: The present disclosure relates to boronic derivatives of hydroxamate compounds, methods for making the same, methods for use as a monotherapy or in combination with one or more other therapeutic agents, for treatment of proliferative diseases such as cancer. The present disclosure also teaches the utilization of said boronic derivatives of hydroxamates as epigenetic therapy medications with enhanced bioavailability, lower-toxicity, and longer-lasting efficacy.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: June 29, 2021
    Assignee: Xavier University of Louisiana
    Inventors: Guangdi Wang, Shilong Zheng, Jiawang Liu, Qiu Zhong, Shanchun Guo
  • Patent number: 11028050
    Abstract: Provided herein are free base crystalline forms and crystalline salts of Compound 1.
    Type: Grant
    Filed: April 17, 2020
    Date of Patent: June 8, 2021
    Assignee: TETRA DISCOVERY PARTNERS, INC.
    Inventors: Mark E. Gurney, Jon P. Lawson, Stephan D. Parent, Richard James Ely
  • Patent number: 11007206
    Abstract: Method of treating or ameliorating a bacterial infection comprising administering a composition comprising a cyclic boronic acid ester compound in combination with a carbapenem antibacterial agent such as Biapenem, and the pharmacokinetics studies thereof are provided.
    Type: Grant
    Filed: January 17, 2020
    Date of Patent: May 18, 2021
    Assignee: MELINTA SUBSIDIARY CORP.
    Inventors: David C. Griffith, Michael N. Dudley, Olga Lomovskaya
  • Patent number: 10973835
    Abstract: A method is disclosed for altering the redox equilibrium of a transmembrane receptor-like protein tyrosine phosphatase (RPTP), particularly a type IIa RPTP, by chemically modulating the activity through contact of such an enzyme with a diaryl boron compound that preferentially reacts with an RPTP in an oxidized state (CyS-OH). This redox modulation is most readily observed and put to use by assaying the inhibition of the phosphatase activity of the RPTP. Such an assay can be carried out on an enzyme in vitro or by contacting the enzyme in a living organism (in vivo). A useful diaryl boron compound corresponds in structure to Formula I in which Ar-1, Ar-2, R1, R2, R3 and R4 are defined within. A pharmaceutical composition containing a useful diaryl boron compound is also disclosed, as are particularly preferred diaryl boron compounds.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: April 13, 2021
    Assignees: The Penn State Research Foundation, Cold Spring Harbor Laboratory
    Inventors: Stephen J. Benkovic, Nicholas K. Tonks, Chun Yu Liu, Navasona Krishnan, Chunliang Liu
  • Patent number: 10959993
    Abstract: The present invention is directed to a combination therapy involving a selective Bcl-2 inhibitor and a MEK inhibitor for the treatment of a patient in need of such a therapy. The patient in need of the combination therapy is suffering from cancer, such as acute myeloid leukemia.
    Type: Grant
    Filed: November 3, 2016
    Date of Patent: March 30, 2021
    Assignee: Genentech, Inc.
    Inventors: Mark Merchant, Deepak Sampath, Marina Konopleva, Lina Han
  • Patent number: 10851118
    Abstract: The invention relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the invention. Also provided herein are methods of treating cancer with the arginase inhibitors of the invention.
    Type: Grant
    Filed: August 10, 2018
    Date of Patent: December 1, 2020
    Assignee: CALITHERA BIOSCIENCES, INC.
    Inventors: Eric B. Sjogren, Jim Li, Michael Van Zandt, Darren Whitehouse
  • Patent number: 10689403
    Abstract: The present invention relates to a method for preparing a four-coordinated organic boron compound, and more specifically, to a method for preparing various and widespread four-coordinated organic boron compounds by directly using an aryl, heteroaryl, or vinyl-functional boronic acid, boroxine, or borate compound as a starting material and adding the compound to any bidentate N,O-ligand, O,O-ligand, or N,N-ligand.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: June 23, 2020
    Assignee: Korea Research Institute of Chemical Technology
    Inventors: Kee In Lee, Venkata Subbaiah Sadu, In Taek Hwang
  • Patent number: 10690675
    Abstract: Compositions and methods for enriching glycocompounds are disclosed which can comprise a glycocompound bound to a boronic acid compound which can be conjugated to a dendrimer.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: June 23, 2020
    Assignee: Georgia Tech Research Corporation
    Inventors: Ronghu Wu, Weixuan Chen
  • Patent number: 10669287
    Abstract: Provided is a compound which is bioapplicable and amyloid-selective, and is useful as an amyloid oxygenation catalyst applicable not only to A? peptides but also to other amyloids, and a preventive/therapeutic drug for an amyloid-related disease using the same.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: June 2, 2020
    Assignee: JAPAN SCIENCE AND TECHNOLOGY AGENCY
    Inventors: Motomu Kanai, Yohei Soma, Jizhi Ni, Atsuhiko Taniguchi
  • Patent number: 10669290
    Abstract: Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
    Type: Grant
    Filed: January 2, 2019
    Date of Patent: June 2, 2020
    Assignee: VENATORX PHARMACEUTICALS, INC.
    Inventors: Christopher J. Burns, Denis Daigle, Bin Liu, Daniel McGarry, Daniel C. Pevear, Robert E. Lee Trout
  • Patent number: 10662140
    Abstract: The present invention relates to a method for skin-whitening using a composition containing resveratryl triglycolate as an active ingredient, and more specifically, relates to a composition for skin-whitening containing resveratryl triglycolate or a cosmetically or pharmaceutically acceptable salt thereof as an active ingredient, a method for skin-whitening including applying or administering a composition containing resveratryl triglycolate or an acceptable salt thereof as an active ingredient to a subject, and a resveratryl triglycolate compound which has a skin-whitening effect, since the resveratryl triglycolate can inhibit melanin synthesis and brighten skin tone.
    Type: Grant
    Filed: November 9, 2016
    Date of Patent: May 26, 2020
    Assignee: KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Yong Chool Boo, Won Choul Park
  • Patent number: 10660909
    Abstract: What is described is a method for treating cancer in a patient in need of such treatment through the use of an antagonist to CXCR1 and/or CXCR2 receptors by administering a therapeutically effective amount of an antagonist of CXCR1 and/or CXCR2, or pharmaceutical compositions thereof, either alone as monotherapy, or in combination with at least one other anticancer therapy.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: May 26, 2020
    Assignee: Syntrix Biosystems Inc.
    Inventors: John A. Zebala, Dean Y. Maeda, Aaron D. Schuler
  • Patent number: 10640520
    Abstract: Compounds of formula (I) are inhibitors of LMP7 and can be employed, inter alia, for the treatment of an autoimmune disorder or hematological malignancies.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: May 5, 2020
    Assignee: MERCK PATENT GMBH
    Inventors: Markus Klein, Oliver Schadt, Philipp Haselmayer, Michael Busch
  • Patent number: 10633399
    Abstract: Disclosed are functionalized aminobenzoboroxoles compounds, method for preparing these compounds, and methods for treating cancers.
    Type: Grant
    Filed: August 15, 2016
    Date of Patent: April 28, 2020
    Assignee: Channel Therapeutics, Inc.
    Inventors: Kandalam V. Ramanujachary, Subash C. Jonnalagadda
  • Patent number: 10626128
    Abstract: Provided is a compound which is bioapplicable and amyloid-selective, and is useful as an amyloid oxygenation catalyst applicable not only to A? peptides but also to other amyloids, and a preventive/therapeutic drug for an amyloid-related disease using the same.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: April 21, 2020
    Assignee: JAPAN SCIENCE AND TECHNOLOGY AGENCY
    Inventors: Motomu Kanai, Yohei Soma, Jizhi Ni, Atsuhiko Taniguchi
  • Patent number: 10618918
    Abstract: Disclosed herein are antimicrobial compounds having the structure of the formula III? pharmaceutical compositions, the use and preparation thereof. The compounds are of the class of boronic acid derivatives, useful for antimicrobial treatment.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: April 14, 2020
    Assignee: QPEX BIOPHARMA, INC.
    Inventors: Scott Hecker, Raja K. Reddy
  • Patent number: 10526348
    Abstract: Provided is a compound which is bioapplicable and amyloid-selective, and is useful as an amyloid oxygenation catalyst applicable not only to A? peptides but also to other amyloids, and a preventive/therapeutic drug for an amyloid-related disease using the same.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: January 7, 2020
    Assignee: JAPAN SCIENCE AND TECHNOLOGY AGENCY
    Inventors: Motomu Kanai, Yohei Soma, Jizhi Ni, Atsuhiko Taniguchi
  • Patent number: 10479805
    Abstract: A beta-lactamase inhibitor having a formula (I). Also provided is a method of using the beta-lactamase inhibitor for prevention or treatment of diseases.
    Type: Grant
    Filed: October 19, 2018
    Date of Patent: November 19, 2019
    Assignee: WUHAN VISION PHARMACEUTICAL TECHNOLOGY CO., LTD.
    Inventors: Shiping Wu, Hongyu Xu, Xiangdong Hu
  • Patent number: 10464952
    Abstract: Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: November 5, 2019
    Assignee: VENATORX PHARMACEUTICALS, INC.
    Inventors: Christopher J. Burns, Daniel C. Pevear, Robert E. Lee Trout, Randy W. Jackson, Jodie Hamrick, Allison L. Zulli, Eugen F. Mesaros, Steven A. Boyd